Reorganizing the Global Pharmacovigilance Function

Summer Foote

An F200 pharma company was reevaluating the operating model of its global drug safety and pharmacovigilance functions. Looking for help assessing cost, quality, and productivity impact of different resourcing scenarios, the group’s head turned to BTG. We delivered an independent pharmacovigilance organization specialist and former engagement lead in Accenture’s life science practice. She worked with internal executives to evaluate the most efficient model, then develop detailed organization-wide communication and implementation plans.

Previous Article
Pharmacovigilance Best Practices: A Q&A With Kerry Coffee
Pharmacovigilance Best Practices: A Q&A With Kerry Coffee

Independent life science consultant Kerry Coffee shares best practices for building efficient pharmacovigil...

Next Article
Redesigning the Regulatory Submissions Process
Redesigning the Regulatory Submissions Process

The internal consulting group at a Fortune 200 pharmaceutical company was redesigning the organization’s re...